The global cellular health screening market was valued at USD 2.78 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030. This growth is anticipated to be driven by an increasing focus on precision medicine, particularly the growing need for analyzing biomarkers associated with aging and overall cellular health. Cellular health screening plays a critical role in assessing how the body responds to various treatments, further fueling market expansion during this period.
However, the COVID-19 pandemic had a significant impact on the market, particularly on companies offering cellular health screening products and services. The pandemic led to a sharp decline in sales and overall testing volumes. Government-imposed restrictions, such as lockdowns and transportation barriers, along with limitations on the import and export of raw materials, severely disrupted supply chains. In response to these challenges and the reduced demand for traditional screening services, many companies adapted by diversifying their product offerings. Some expanded into COVID-19 molecular and antibody testing to maintain market relevance and offset declines in their core business activities.
Gather more insights about the market drivers, restrains and growth of the Cellular Health Screening Market
Sample Type Segmentation Insights
In 2022, the blood sample segment led the market with a 47.41% share. This dominance can be attributed to the widespread use of blood samples by healthcare professionals for diagnosing various diseases, assessing organ function, and evaluating risk factors. Additionally, the development of new diagnostic devices that utilize blood for detection and screening is contributing to the growth of this segment. For example, Osler, a blood-testing startup, is seeking investor funding to launch a new diagnostic device designed to deliver results in just 10 minutes, making blood tests more affordable and accessible.
The urine sample segment held the second-largest market share and is expected to experience substantial growth during the forecast period. Urine collection is a patient-friendly and non-invasive process that can be completed quickly without requiring specialized personnel. Furthermore, research has demonstrated that urine screening can be effectively used to assess oxidative stress levels in the body. For instance, a study published in July 2020 by Japanese researchers found that the presence of pteridine derivatives in urine could be linked to oxidative stress and smoking. As interest in evaluating oxidative stress rises, the demand for urine-based cellular health screening is expected to grow as well.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
